[go: up one dir, main page]

ES2078175B1 - Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones. - Google Patents

Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.

Info

Publication number
ES2078175B1
ES2078175B1 ES09302735A ES9302735A ES2078175B1 ES 2078175 B1 ES2078175 B1 ES 2078175B1 ES 09302735 A ES09302735 A ES 09302735A ES 9302735 A ES9302735 A ES 9302735A ES 2078175 B1 ES2078175 B1 ES 2078175B1
Authority
ES
Spain
Prior art keywords
tobramycin
clobetasone
applications
pharmaceutical formulation
formulation containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09302735A
Other languages
English (en)
Other versions
ES2078175A1 (es
Inventor
Michael Van Wie Bergamini
Cabrera Antonio Lopez
Mas Jose Alberto Vallet
Laguens Carmen Oros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Cusi SA
Original Assignee
Laboratorios Cusi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Cusi SA filed Critical Laboratorios Cusi SA
Priority to ES09302735A priority Critical patent/ES2078175B1/es
Priority to EP94203756A priority patent/EP0661055A1/en
Priority to JP7000087A priority patent/JPH07309763A/ja
Publication of ES2078175A1 publication Critical patent/ES2078175A1/es
Application granted granted Critical
Publication of ES2078175B1 publication Critical patent/ES2078175B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULACION FARMACEUTICA CONTENIENDO CLOBETASONA Y TOBRAMICINA Y SUS APLICACIONES. LA COMPOSICION COMPRENDE: 0,001-5,0 POR CIENTO DE CLOBETASONA O UN ISOMERO O UN DERIVADO O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES; 0,05-5,0 POR CIENTO DE TOBRAMICINA O UN ISOMERO O UN DERIVADO O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES; Y, OPCIONALMENTE, UNO O MAS INGREDIENTES SELECCIONADOS ENTRE AGENTES ISOTONIZANTES, AMORTIGUADORES DEL PH, VISCOSIZANTES, HUMECTANTES, QUELANTES, ANTIOXIDANTES, CONSERVADORES, SOLUBILIZANTES, ADEMAS DE UNO O VARIOS EXCIPIENTES ADECUADOS A LA FORMA DE PRESENTACION FARMACEUTICA DE LA FORMULACION. DICHA FORMULACION PRESENTA UN PH COMPRENDIDO ENTRE 4 Y 9. APLICACION PARA EL TRATAMIENTO DE LOS PROCESOS INFLAMATORIOS OCULARES Y OTICOS ACOMPAÑADOS DE INFECCION.
ES09302735A 1993-12-31 1993-12-31 Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones. Expired - Lifetime ES2078175B1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES09302735A ES2078175B1 (es) 1993-12-31 1993-12-31 Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
EP94203756A EP0661055A1 (en) 1993-12-31 1994-12-23 Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof
JP7000087A JPH07309763A (ja) 1993-12-31 1995-01-04 クロベタゾンおよびトブラマイシンを含有する医薬製剤とその応用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09302735A ES2078175B1 (es) 1993-12-31 1993-12-31 Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.

Publications (2)

Publication Number Publication Date
ES2078175A1 ES2078175A1 (es) 1995-12-01
ES2078175B1 true ES2078175B1 (es) 1996-10-16

Family

ID=8284085

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09302735A Expired - Lifetime ES2078175B1 (es) 1993-12-31 1993-12-31 Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.

Country Status (3)

Country Link
EP (1) EP0661055A1 (es)
JP (1) JPH07309763A (es)
ES (1) ES2078175B1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0752245B1 (en) * 1995-07-05 2002-05-22 European Community Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery
AU9281698A (en) * 1997-10-01 1999-04-23 Wakamoto Pharmaceutical Co., Ltd. O/w emulsion compositions
MXPA02003130A (es) 1999-09-24 2004-04-21 Alcon Inc Formulaciones topicas en suspension que contienen ciprofloxacino y dexametasona.
FR2802097B1 (fr) * 1999-12-14 2002-12-13 Invest S Therapeutiques Essais Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
CA2412575C (en) 2000-07-26 2009-12-29 Onkar N. Singh Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
EP1429780B1 (en) 2001-09-21 2005-12-21 Alcon, Inc. Method of treating middle ear infections
JP2006257080A (ja) * 2005-02-18 2006-09-28 Santen Pharmaceut Co Ltd ステロイド化合物の副作用軽減または回避方法
US20080166417A1 (en) * 2005-02-18 2008-07-10 Kazuhito Yamada Method of Relieving or Avoiding Side Effect of Steroid
CA2602577C (en) * 2005-10-18 2015-03-31 Allergan, Inc. Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
EP2349278A1 (en) * 2008-10-21 2011-08-03 Gilead Sciences, Inc. Fosfomycin/tobramycin combinations for the treatment and prevention of ophthalmic, otological and dermatological infections
BRPI1007318A2 (pt) * 2009-01-23 2019-04-09 Qlt Inc. distribuição com liberação sustentada de um ou mais agentes.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1253831A (en) * 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
JP2617139B2 (ja) * 1988-03-09 1997-06-04 アルコン ラボラトリーズ インコーポレイテッド 局所的眼科用途の為のトブラマイシンとステロイドの組合わせ
AU610175B2 (en) * 1988-05-25 1991-05-16 Biogal Gyogyszergyar Pharmaceutical composition comprising a compound containing sulfhydryl group(s) for the treatment of otitis

Also Published As

Publication number Publication date
EP0661055A1 (en) 1995-07-05
JPH07309763A (ja) 1995-11-28
ES2078175A1 (es) 1995-12-01

Similar Documents

Publication Publication Date Title
ES2079320B1 (es) Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
ES2175020T3 (es) Formulacion oftalmica para el uso en la cirugia ocular.
ES2078175B1 (es) Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
ES2084944T3 (es) Amidas terapeuticas.
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DE59400489D1 (de) Fungizide Wirkstoffkombinationen
MX9307555A (es) Derivados de paclitaxel y formulaciones farmaceuticas que los contienen.
ES2156155T3 (es) Derivado de pirazol.
ES2065846B1 (es) Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
FI934298A0 (fi) Kristallin tiagabine-hydrokloridmonohydrat, dess framstaellning och dess anvaendning
ES2109993T3 (es) Derivados de 4-desoxi-4-epipodofilotoxina o sus sales farmaceuticamente aceptables.
MX2025005474A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida
ES2121597T3 (es) Derivados de bencenosulfonamida para el tratamiento de la inestabilidad de la vejiga.
MX9300399A (es) Derivados heterotriciclicos.
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
ATE173930T1 (de) Pharmazeutische zusammensetzungen zur topischen anwendung die ein chelatierungsmittel, ein tocopherol und einen antimikrobiellen wirkstoff enthalten
ES2141843T3 (es) Utilizacion de amidoaminas en composiciones oftalmologicas.
DK0533516T3 (da) Hidtil ukendte 1-(alkoxybenzyl)piperazinamidforbindelser, fremgangsmåder til fremstilling heraf og farmaceutiske midler, som indeholder dem
CA2042936A1 (en) Treatment of ocular hypertension with a synergistic combination for ophthalmic use
ES2097127T3 (es) Formulaciones de administracion topica eficaces para el control de parasitos internos y externos de animales homotermos.
LV10921A (lv) Jaunas farmaceitiskas kompozicijas
ES2065192T3 (es) Nuevos nicotinatos de diacil-glicerol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR046043A1 (es) Asociacion de un agente anti-aterotrombotico y un agente anti-agregacion de plaquetas y composiciones farmaceuticas que los contienen
GT199300041A (es) Derivados de hidrazona, proceso para producir los mismos, insecticidas y/o acaricidas que contienen dichos derivados co-mo ingrediente activo y compuestos intermedios para producir dichos derivados.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19931231

Kind code of ref document: B1

Effective date: 19931231

FA2A Application withdrawn

Effective date: 19970317